Oncotelic Therapeutics, Inc. (OTLC) — SEC Filings
Oncotelic Therapeutics, Inc. (OTLC) — 21 SEC filings. Latest: 8-K (Apr 2, 2026). Includes 11 8-K, 6 10-Q, 2 10-K.
View Oncotelic Therapeutics, Inc. on SEC EDGAR
Overview
Oncotelic Therapeutics, Inc. (OTLC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1/A filed on Dec 22, 2025: Oncotelic Therapeutics, Inc. (OTLC) filed an S-1/A on December 22, 2025, for the resale of 115,600,000 shares of common stock by Mast Hill Fund, LP, representing 20.1% of the company's outstanding shares. The shares stem from a Securities Purchase Agreement on July 31, 2025, and an Equity Purchase A
Sentiment Summary
Across 21 filings, the sentiment breakdown is: 3 bearish, 16 neutral, 2 mixed. The dominant filing sentiment for Oncotelic Therapeutics, Inc. is neutral.
Filing Type Overview
Oncotelic Therapeutics, Inc. (OTLC) has filed 11 8-K, 1 S-1/A, 1 S-1, 6 10-Q, 2 10-K with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (21)
Risk Profile
Risk Assessment: Of OTLC's 15 recent filings, 4 were flagged as high-risk, 9 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$1,068,225 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $409,000 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | $10,328,100 |
Key Executives
- Vuong Trieu
- James A Mercer III
Industry Context
Oncotelic Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on orphan oncology indications. This niche targets rare cancers, which may offer regulatory advantages but also presents challenges in patient recruitment for clinical trials and market size. The industry is characterized by long development cycles, high failure rates, and significant reliance on scientific innovation and regulatory approvals.
Top Tags
Biotechnology (4) · 10-Q (4) · Going Concern (3) · financials (3) · Orphan Drugs (2) · Clinical Stage (2) · equity-sale (2) · Oncology (2) · Convertible Debt (2) · 8-k (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Shares of common stock for resale | 115,600,000 | May be offered by Mast Hill Fund, LP |
| Percentage of outstanding common stock | 20.1% | Represents the shares Mast Hill may sell relative to the fully diluted outstanding shares |
| Last reported sales price per share | $0.0940 | Oncotelic's common stock price on December 17, 2025 |
| Date of Securities Purchase Agreement | July 31, 2025 | Agreement under which shares were transferred to Mast Hill |
| Date of Equity Purchase Agreement | August 1, 2025 | Agreement under which shares were transferred to Mast Hill |
| Shares from put notices | 100,000,000 | Issuable to Mast Hill under the Equity Purchase Agreement |
| Shares from warrant exercises | 5,350,000 | Total shares underlying warrants from both agreements |
| Shares from debt conversion | 8,000,000 | Issuable to Mast Hill upon conversion of indebtedness under the Note Purchase Agreement |
| Commitment Fee Shares | 2,250,000 | Issued to Mast Hill under the Note Purchase Agreement |
| Date of Joint Venture formation | March 2022 | Oncotelic entered into a JV with Dragon to form GMP Biotechnology, Limited |
| Shares for Resale | 309,717,647 | Number of common stock shares Mast Hill Fund, LP may offer, representing a significant market overhang. |
| Percentage of Outstanding Stock | 39.1% | The proportion of Oncotelic's common stock that Mast Hill Fund, LP may sell, indicating substantial potential dilution. |
| Last Reported Stock Price | $0.0850 | The closing price of OTLC common stock on November 17, 2025, highlighting its penny stock status and low valuation. |
| Shares from Put Notices | 294,117,647 | The maximum number of shares Oncotelic may issue to Mast Hill under the Equity Purchase Agreement, from which Oncotelic receives cash proceeds. |
| Shares from Note Conversion | 8,000,000 | Shares issuable to Mast Hill upon conversion of indebtedness under the Note Purchase Agreement. |
Frequently Asked Questions
What are the latest SEC filings for Oncotelic Therapeutics, Inc. (OTLC)?
Oncotelic Therapeutics, Inc. has 21 recent SEC filings from Feb 2024 to Apr 2026, including 11 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OTLC filings?
Across 21 filings, the sentiment breakdown is: 3 bearish, 16 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Oncotelic Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Oncotelic Therapeutics, Inc. (OTLC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Oncotelic Therapeutics, Inc.?
Key financial highlights from Oncotelic Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OTLC?
The investment thesis for OTLC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Oncotelic Therapeutics, Inc.?
Key executives identified across Oncotelic Therapeutics, Inc.'s filings include Vuong Trieu, James A Mercer III.
What are the main risk factors for Oncotelic Therapeutics, Inc. stock?
Of OTLC's 15 assessed filings, 4 were flagged high-risk, 9 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Oncotelic Therapeutics, Inc.?
Forward guidance and predictions for Oncotelic Therapeutics, Inc. are extracted from SEC filings as they are enriched.